Correlation Engine 2.0
Clear Search sequence regions


  • acquaintance (1)
  • cancer (1)
  • humans (1)
  • patients (2)
  • phase (3)
  • therapies (2)
  • thyroid (5)
  • thyroid cancer (3)
  • Sizes of these terms reflect their relevance to your search.

    We review the new systemic treatment strategies for differentiated thyroid carcinoma, as well as the acquaintance of its molecular biology. Multiple kinase inhibitor drugs have become the standard therapy for thyroid cancer, albeit several adverse effects. In the last few years, new molecules have raised with an overall safety profile. Most of them, are considered targeted therapies directed toward driven-molecules alterations, such as neurotrophic tyrosine kinase receptor (NTRK) inhibitors for NTRK-fusion thyroid cancer and rearranged during transfection (RET) inhibitors for RET-fusion thyroid cancer. Recently, promising outcomes and safety data have been presented. Furthermore, other novel strategies for advanced thyroid carcinoma are currently investigated in clinical trials.The ability to provide precision medicine to patients in routine clinical settings depends on the availability of molecular profiling test at their cancer centers. The impossibility to perform molecular characterization could turn out to be a diagnostic and treatment limitation for some patients. The treatment of advanced differentiated thyroid carcinoma has undergone rapid evolution in the last decade. An emerging treatment era is coming. From now to then, we will need to face the different types of diagnostic tools for molecular characterization, their interpretation and, finally the access to targeted therapies. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

    Citation

    Neus Basté, Mireia Mora, Juan José Grau. Emerging systemic antitarget treatment for differentiated thyroid carcinoma. Current opinion in oncology. 2021 May 01;33(3):184-195

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33720068

    View Full Text